.webp&w=3840&q=75)
Lilly (NYSE:LLY) signed a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, adding precision biologics programs targeting autoimmune and allergic diseases.
Eli Lilly and Company (NYSE:LLY) filed six lawsuits against U.S. businesses accused of selling black-market retatrutide products, while the company continues efforts to report illegal sales to regulators and law enforcement.
Eli Lilly (NYSE:LLY) announced positive topline Phase 3 results for its investigational triple agonist, retatrutide, from the 80-week TRIUMPH-2 and TRIUMPH-3 clinical trials.
Eli Lilly (NYSE:LLY) executed a definitive agreement to acquire AtaiBeckley (NASDAQ:ATAI) for a $2.8 billion upfront equity valuation.
Lilly (NYSE:LLY) reported second-quarter revenue of $23 billion, up 48%, as demand for Mounjaro and Zepbound supported volume growth.
